Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Experience with sustained-release melatonin for the treatment of sleep disorders in depression

https://doi.org/10.14412/2074-2711-2015-3-46-50

Full Text:

Abstract

The data available in the literature on the role of melatonin in the regulation of circadian rhythms and sleep disorders in the population and in patients with mental diseases are analyzed. The cause of insomnia may be circadian rhythm disorders due to the age-related decline in the elaboration of the endogenous hormones that are responsible for the quality and duration of sleep, one of which is melatonin.

Sustained-release melatonin is a synthetic analogue of the endogenous human pineal hormone melatonin. According to clinical findings, the main proven clinical effects of sustained-release melatonin 2 mg are a reduction in the latency of sleep, improvement of its quality, and lack of daytime sleepiness. The drug causes no dependence on its long use and rebound symptoms (increased insomnia symptoms), positively affects cognitive functions, and lowers nocturnal blood pressure in hypertensive patients.

The paper describes a clinical case of a female patient with recurrent depressive disorder, in whom sustained-release melatonin 2 mg has demonstrated high efficacy and good tolerability in the combination therapy of sleep disorders in the pattern of depression.

About the Authors

Svetlana Vladimirovna Prokhorova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Psychiatry,

8, Trubetskaya St., Build. 2, Moscow 119048



T. N. Maksimova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Psychiatry,

8, Trubetskaya St., Build. 2, Moscow 119048



References

1. Левин ЯИ. Клиническая сомнология: проблемы и решения. Неврологический журнал. 2004;9(4):4-13. [Levin YaI. Clinical somnology: problems and solutions. Nevrologicheskii zhurnal. 2004;9(4):4-13. (In Russ.)].

2. Тювина НА, Щукина ЕП, Изотова ЕА. Расстройства сна при психических заболеваниях и их коррекция. Неврология, нейропсихиатрия, психосоматика. 2012;4(1):105-11. [Tyuvina NA, Shchukina EP, Izotova EA. Sleep disorders in mental diseases and their correction. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry,Psychosomatics. 2012;4(1):105-11. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-372

3. American Academy of Sleep Medicine. International classification of sleep disorders. 2nd ed.: Diagnostic and coding manual. Westchester, Ill.: American Academy of Sleep Medicine, 2005.

4. Zammit GK. The prevalence, morbidities, and treatments of insomnia. CNS Neurol Disord Drug Targets. 2007 Feb;6(1):3-16.

5. Schwartz S, McDowell Anderson W, Cole SR, et al. Insomnia and heart disease: a review of epidemiologic studies. J Psychosom Res. 1999 Oct;47(4):313-33.

6. Abad VC, Sarinas P, Guilleminault C. Sleep and rheumatologic disorders. Sleep Med Rev. 2008 Jun;12(3):211-28. doi: 10.1016/j.smrv.2007.09.001.

7. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med. 2008 Oct 15;4(5):487-504.

8. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996 Mar 15;39(6): 411-8.

9. McCall WV, Reboussin BA, Cohen W. Subjective measurement of insomnia and quality of life in depressed inpatients. J Sleep Res. 2000 Mar;9(1):43-8.

10. Левин ЯИ. Депрессия и сон. Лечащий врач. 2008;(8):29-32. [Levin YaI. Depression and sleeping. Lechashchii vrach. 2008;(8):29-32. (In Russ.)].

11. Шацберг АФ, Коул ДжО, ДеБаттиста Ч. Руководство по клинической психофармакологии. Москва: МЕДпресс-информ; 2013. 608 c. [Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. Moscow: MEDpress-inform; 2013. 608 p.]

12. Данилов ДС. Алпразолам: возможности использования на современном этапе развития фармакотерапии психических расстройств. Томск: Иван Федоров; 2013. 56 с. [Danilov DS. Alprazolam: vozmozhnosti ispol'zovaniya na sovremennom etape razvitiya farmakoterapii psikhicheskikh rasstroistv [Alprazolam: use at the present stage of development of pharmacotherapy of mental disorders]. Tomsk: Ivan Fedorov; 2013. 56 p.]

13. Клиническая фармакология по Гудману и Гилману. Москва: Практика; 2006. 1648 с. [Clinical pharmacology by Goodman and Gilman. Moscow: Praktika; 2006. 1648 p.]

14. Анисимов ВН. Мелатонин и его место в современной медицине. Русский Медицинский Журнал. 2006;14(4):269-73. [Anisimov VN. Melatonin and its place in modern medicine. Russkii Meditsinskii Zhurnal. 2006;14(4):269-73. (In Russ.)].

15. Арушанян ЭБ. Гормон эпифиза мелатонин и его лечебные возможности. Русский Медицинский Журнал. 2005;13(26):1755-60. [Arushanyan EB. The hormone of the pineal gland melatonin and its therapeutic potential. Russkii Meditsinskii Zhurnal. 2005;13(26):1755-60. (In Russ.)].

16. Waldhauser F, Weiszenbacher G, Tatzer E, et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab. 1988 Mar;66(3): 648-52.

17. Sharma M, Palacios-Bois J, Schwartz G, et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry. 1989 Feb 1;25(3):305-19.

18. Circadin® 2 mg prolonged-release tablets. Summary of product characteristics. 2008. www.ema.europa.eu/ema/index.jsp?curl=pages /medicines/human/medicines/000695/humanmed_000701.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true

19. Circadin: European Medicines Agency Public Assessment Reports for Circadin. ww.emea.europa.eu/humandocs/Humans/EPAR/circadin/circadin.htm

20. European Medicines Agency. Circadin: Product Information (SPC). www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000695/WC500026811.pdf

21. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol. 2006 Jun;61(6):761-6.

22. Buscemi N, Vandermeer B, Hooton N, et al. The efficacyand safety of exogenous melatonin for primary sleep disorders. A metaanalysis. J Gen Intern Med. 2005 Dec;20(12):1151-8.

23. Garfinkel D, Zorin M, Wainstein J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307-13. doi: 10.2147/DMSO.S23904. Epub 2011 Aug 2.

24. Мальцева ЛИ, Гафарова ЕА. Роль мелатонина в развитии климактерического синдрома у женщин и возможности применения мелатонина в лечении симптомов патологического климакса. Русский медицинский журнал. 2007;(4):266-99. [Mal'tseva LI, Gafarova EA. The role of melatonin in the development of climacteric syndrome in women and the possible application of melatonin in the treatment of pathological symptoms of menopause. Russkii meditsinskii zhurnal. 2007;(4):266-99. (In Russ.)].


For citation:


Prokhorova S.V., Maksimova T.N. Experience with sustained-release melatonin for the treatment of sleep disorders in depression. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):46-50. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-46-50

Views: 428


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)